Replies to post #37176 on Innovation Pharmaceuticals Inc (IPIX)

[Whooops]

Welcome Orion, its truly amazing how tasty that beef is. Mind-boggling potential if one does some research here. You may also want to read these if not already (published/presented):

http://cellceutix.com/wp-content/uploads/pdfs/AACR%20poster2012MAR29%2011x17%20FINAL.pdf

http://cellceutix.com/wp-content/uploads/pdfs/AACR%20poster2011APR-11x17.pdf

http://cellceutix.com/wp-content/uploads/2012/07/ACS-poster-2012-v10-11x17.pdf

http://cellceutix.com/wp-content/uploads/2012/07/ASCO-poster-Kevetrin-2013-JUN-03-FINAL.pdf

[tootalljones]

orion nebula, welcome!

[tootalljones]

well stated by seelisa about publication vs. Kevi

"This is an excellent read to explain the behavior of a developing biotech: http://bit.ly/12rm9Gh
If the development of Kevetrin was based on a molecule with origins in academia research, there would be much information available for review. The goal of academia is to research and disseminate research information. The goal of a business developing a proprietary product is to maintain rigid control of property information until property is brought to market. Huge difference in approach. This excerpt from the Entrepreneurs Guide to a Biotech Startup shows the typical method followed by the biotech firm dealing with novel agent: “The Company has done nothing to compromise the secrecy, confidentiality or value of any of its intellectual property required to conduct its business as it is currently being conducted or as proposed to be conducted...The components of an Intellectual Property Ownership Program would include: 1) A centralization of information that limits access to the company’s patents, know-how, confidential information, and trade secrets; 2) The right to review, delay and possibly edit the publication of any article to provide the company an opportunity to
file patent applications..." Cellceutix, in early stages of development of novel agent, has successfully maintained its business strategy and protected its property at every step. At this tender stage in their own development, this approach of maintaining strict confidentiality is both desirable and necessary for the company's success."

[BonelessCat]

K vs. K562 Leukemia cell line. Looks pretty effective to me: